A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA

Peking Union Medical College Hospital90 enrolled

Overview

Aplastic anemia (AA) is a group of clinical syndromes. Treatment options are very limited. The results of a previous clinical study showed good efficacy and a high safety profile of herombopag in improving thrombocytopenia, but this result needs to be supported by more data. In our study, patients who were willing to participate in this study and were diagnosed with transfusion-dependent non-heavy aplastic anemia were randomized to the rhTPO combined with herombopag + cyclosporine group and given rhTPO (at a dose of 1500 U by subcutaneous injection once daily for 7 d, 28 d for 3 courses) +Herombopag(10 mg/day for 3 months) + cyclosporine (3-5 mg/kg/d for 3 months). -5 mg/kg/d for at least 6 months) and herombopag + cyclosporine (10 mg/day for 3 months) + cyclosporine (3-5 mg/kg/d for at least 6 months) in the herombopag+ cyclosporine group to observe the efficacy and safety.

Aplastic anemia (AA) is a group of clinical syndromes caused by a significant decrease in bone marrow hematopoietic tissue from different etiologies, resulting in hematopoietic failure. The prevalence of AA in China is 7.4 per 1 million. It peaks in the 15-25 and 60+ age groups and is more common in men than women. Treatment options are very limited. The results of a previous clinical study showed good efficacy and a high safety profile of herombopag in improving thrombocytopenia, but this result needs to be supported by more data. In our study, patients who were willing to participate in this study and were diagnosed with transfusion-dependent non-heavy aplastic anemia were randomized to the rhTPO combined with herombopag + cyclosporine group and given rhTPO (at a dose of 1500 U by subcutaneous injection once daily for 7 d, 28 d for 3 courses) +Herombopag(10 mg/day for 3 months) + cyclosporine (3-5 mg/kg/d for 3 months). -5 mg/kg/d for at least 6 months) and Herombopag + cyclosporine (10 mg/day for 3 months) + cyclosporine (3-5 mg/kg/d for at least 6 months) in the herombopag+ cyclosporine group to observe the efficacy and safety.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥18 years old. 2. Clearly diagnosed untreated NSAA. 3. At least one of the following conditions was met at the time of enrollment: hemoglobin \<90 g/L. Platelet \<30×109/L, neutrophils \<1.0×109/L. 4. Baseline liver and kidney function (ALT, AST, Cr) was less than 2 times the normal value. 5. No active infection; Not pregnant or breastfeeding. 6. Agree to sign the consent form. 7. The Eastern Cancer Collaboration Group (ECOG) score was 0-2. Exclusion Criteria: 1. pancytopenia caused by other causes, such as myelodysplastic syndrome (MDS). 2. There is cytogenetic evidence of clonal hematologic bone marrow diseases (MDS, AML). 3. PNH clone ≥50%. 4. Had received hematopoietic stem cell transplantation (HSCT) before enrollment. 5. Immunosuppressive therapy such as ATG or cyclosporine use for more than 2 weeks. 6. Infection or bleeding that is not controlled by standard treatment. 7. Allergic to recombinant TPO or Hitrepopar. 8. Active HIV, HCV or HBV infection or cirrhosis or portal hypertension. 9. Any concomitant malignancy or local basal cell carcinoma of the skin within 5 years. 10. Previous history of thromboembolic events, heart attack or stroke (including antiphospholipid antibody syndrome) and current use of anticoagulants. 11. Women who are pregnant or nursing (lactation). 12. Have participated in other clinical trials within 3 months.

Outcomes

Primary Outcomes

ORR at 3 Months

After 3 months of treatment, ORR was calculated by measuring platelets, hemoglobin, neutrophils, and transfusion independence

Time frame: Week 14

ORR at 6 Months

After 6 months of treatment, ORR was calculated by measuring platelets, hemoglobin, neutrophils, and transfusion independence

Time frame: Week 26

Secondary Outcomes

3 months of drug safety

Assessing the incidence and severity of adverse events; All adverse events that occur or worsen within 3 months of treatment will be reported

Time frame: Week 14

6 months of drug safety

Assessing the incidence and severity of adverse events; All adverse events that occur or worsen within 6 months of treatment will be reported

Time frame: Week 26

A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts